Chest · 1997
Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.
Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеКомментарийНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z
Аннотация
STUDY OBJECTIVES: To determine the risk factors and frequency of intracranial hemorrhage among patients undergoing thrombolysis for pulmonary embolism.
DESIGN: A retrospective descriptive and controlled analysis.
SETTING: Hospitalized patients at centers in the United States, Canada, and Italy.
PATIENTS: All had evidence of pulmonary embolism on perfusion scans or angiography.
INTERVENTIONS: None.
MEASUREMENTS AND RESULTS: Data were analyzed on 312 patients from five previously reported studies of pulmonary embolism thrombolysis. The frequency of intracranial hemorrhage up to 14 days after pulmonary embolism thrombolysis was 6 of 312 or 1.9% (95% confidence interval, 0.7 to 4.1%). Two of six intracranial hemorrhages were fatal. Two of the six patients received thrombolysis in violation of the protocol because they had pre-existing, known intracranial disease. Average diastolic BP at the time of hospital admission was significantly elevated in patients who developed an intracranial hemorrhage (90.3 +/- 15.1 mm Hg) compared with those who did not (77.6 +/- 10.9 mm Hg; p = 0.04). Other baseline characteristics and laboratory data were similar in both groups. Decreased level of consciousness, hemiparesis, and visual field deficits were the most common clinical signs of intracranial hemorrhage.
CONCLUSIONS: Intracranial hemorrhage after pulmonary embolism thrombolysis is an infrequent but often grave complication. Meticulous patient screening before administering thrombolysis is imperative. Diastolic hypertension at the time of hospital admission is a risk factor for intracranial hemorrhage after pulmonary embolism thrombolysis.
DESIGN: A retrospective descriptive and controlled analysis.
SETTING: Hospitalized patients at centers in the United States, Canada, and Italy.
PATIENTS: All had evidence of pulmonary embolism on perfusion scans or angiography.
INTERVENTIONS: None.
MEASUREMENTS AND RESULTS: Data were analyzed on 312 patients from five previously reported studies of pulmonary embolism thrombolysis. The frequency of intracranial hemorrhage up to 14 days after pulmonary embolism thrombolysis was 6 of 312 or 1.9% (95% confidence interval, 0.7 to 4.1%). Two of six intracranial hemorrhages were fatal. Two of the six patients received thrombolysis in violation of the protocol because they had pre-existing, known intracranial disease. Average diastolic BP at the time of hospital admission was significantly elevated in patients who developed an intracranial hemorrhage (90.3 +/- 15.1 mm Hg) compared with those who did not (77.6 +/- 10.9 mm Hg; p = 0.04). Other baseline characteristics and laboratory data were similar in both groups. Decreased level of consciousness, hemiparesis, and visual field deficits were the most common clinical signs of intracranial hemorrhage.
CONCLUSIONS: Intracranial hemorrhage after pulmonary embolism thrombolysis is an infrequent but often grave complication. Meticulous patient screening before administering thrombolysis is imperative. Diastolic hypertension at the time of hospital admission is a risk factor for intracranial hemorrhage after pulmonary embolism thrombolysis.
Предметные рубрики MeSH
AgedAngiographyBlood PressureCause of DeathCerebral HemorrhageConsciousnessDiastoleFemaleFibrinolytic AgentsHemiplegiaHumansHypertensionMaleMiddle AgedPatient AdmissionPatient SelectionPulmonary EmbolismRadionuclide ImagingRetrospective StudiesRisk FactorsThrombolytic TherapyTime FactorsVision DisordersVisual Fields